Novo Nordisk A/S Common Stock (NVO)

Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.

Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.

The worst may be in the rearview mirror for the drugmaker.

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease.

This company aims to serve a market heading toward $100 billion.

Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.

Netflix, Uber, and Novo Nordisk are all excellent, undervalued stocks to buy today.

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company.

You might regret ignoring these companies at current levels.

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.

Duquesne Family Office has beefed up its healthcare holdings.

Could this little-known biotech be a hidden gem?

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.

They are way more than just GLP-1 stocks.

The U.K.'s health regulator just approved Eli Lilly's new weight-loss pill, a huge win for the drug maker.

The stock continues to look unstoppable.

It's yet another setback for the drugmaker.

Hims & Hers topped Q2 revenue estimates and raised guidance, but missed EPS forecasts, posted a wider net loss, and faces an FTC lawsuit, leaving Wall Street cautious with a Hold rating.

Sales of weight loss treatments have been incredible for Novo Nordisk.

Novo Nordisk is playing catch-up in the GLP-1 race.

One of its more popular products just got the green light from a major national regulator.